Cardiothoracic & vascular anesthesia
Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial
Authors' conclusion
The effect of AA on AKI was consistent across subgroups, whereas they had opposing effects on survival in patients receiving brief or prolonged study drug infusion and in favour of the brief infusion group.
Study context
- Population
- Adults undergoing cardiac surgery in the PROTECTION trial3,481 with available data
- Participants
- 3,511 adults
- Comparison
- Amino acids (AA) vs placebo, by brief or prolonged infusion
- Primary endpoint
- Consistency of direction of AA effects on AKI and ICU mortality across subgroups
Methodological detailspost hoc, double-blind, placebo-controlled, subgroup analysis
- Post hoc
- Double-blind
- Placebo-controlled
- Subgroup analysis
Primary result
As reported in the abstract
AKI
Brief: Acute kidney injury (AKI) risk reduction (25% to 21%)
3.8%
Prolonged: AKI risk reduction (44% to 38%)
5.7%
Further findings
ICU mortality
- Brief: reduction (placebo vs AA)
- 1.9% to 1.0%
- Prolonged: increase (placebo vs AA)
- 2.5% to 3.5%
- Discordant effects
- Interaction P=0.04
Use of RRT
- Reduced with brief AA infusion; no effect with prolonged infusion
Original publication
Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial. Br J Anaesth. Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →